Press Release: Dupixent Approved As The First-Ever Biologic Medicine In Japan For Patients With COPD
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD <li /> Following recent approvals in the E ...
About Dupixent Dupixent is available in Japan in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available for COPD. Dupixent is intended for injection under the skin (subcutaneous ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
14h
Zacks Investment Research on MSNNTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New IndicationIntellia Therapeutics NTLA announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation ...
Regeneron Pharmaceuticals just belly-flopped into a fresh 12-month low, trading as low as $640.28—Wall Street winced. Analyst ...
Students from Salem High School on March 20 participated in the New Hampshire Science and Engineering Expo held at NHTI, ...
An ʻIolani School senior recently took home a top prize at the nation’s oldest science research competition for high school students. Logan Lee traveled to Washington, D.C., earlier this month for the ...
American Century Companies trimmed its stake in Regeneron Pharmaceuticals by 4.2% during Q4, selling nearly 31,000 shares and ...
We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ...
Superintendent Dr. Drew Patrick congratulated eleven Scarsdale High School juniors and seniors who took part in this year’s ...
Regeneron Pharmaceuticals Inc. closed 47.64% short of its 52-week high of $1,211.20, which the company reached on August 27th.
We recently published a list of 11 Best Extremely Profitable Stocks to Buy According to Analysts. In this article, we are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results